Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis

Current Diabetes Reports

Volumn 3, Issue 3, 2003, Pages 248-254

  Theuma, Pierre ^a   Fonseca, Vivian A ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; FIBRINOGEN; HAPTOGLOBIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 18; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OROSOMUCOID; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; URIC ACID; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR; ARTERIOSCLEROSIS; BLOOD; DIABETES MELLITUS; DIABETIC ANGIOPATHY; OBESITY; PATHOPHYSIOLOGY;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HOMOCYSTEINE; HUMANS; INFLAMMATION; OBESITY; RISK FACTORS;

EID: 0042020271     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-003-0072-3     Document Type: Review

References (57)

1. Colwell JA: Vascular thrombosis in type II diabetes mellitus. Diabetes 1993, 42:8-11.
2. Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. JAMA 1999, 281:1291-1297.
3. Ridker PM: Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999, 130:933-937.
4. Barnes PJ, Karin M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997, 336:1066-1071.
5. De Caterina R, Libby P, Peng HB, et al.: Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995, 96:60-68.
6. Lee RT, Yamamoto C, Feng Y, et al.: Mechanical strain induces specific changes in the synthesis and organization of proteoglycans by vascular smooth muscle cells. J Biol Chem 2001, 276:13847-13851.
7. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
8. Roivainen M, Viik-Kajander M, Palosuo T, et al.: Infections, inflammation, and the risk of coronary heart disease. Circulation 2000, 101:252-257.
9. Vita JA, Loscalzo J: Shouldering the risk factor burden: infection, atherosclerosis, and the vascular endothelium. Circulation 2002, 106:164-166.
10. Stemme S, Faber B, Holm J, et al.: T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995, 92:3893-3897.
11. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999, 19:972-978.
12. Schmidt AM, Yan SD, Wautier JL, Stern D: Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999, 84:489-497.
13. Jialal I, Devaraj S: Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. Am J Clin Pathol 2001, 116(suppl):S108-S115.
14. Rifai N, Tracy RP, Ridker PM: Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999, 45:2136-2141.
15. Burke AP, Tracy RP, Kolodgie F, et al.: Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 2002, 105:2019-2023.
16. Venugopal SK, Devaraj S, Yuhanna I, et al.: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002, 106:1439-1441.
17. Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
18. Ridker PM, Buring JE, Shih J, et al.: Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998, 98:731-733.
19. Rifai N, Buring JE, Lee IM, et al.: Is C-reactive protein specific for vascular disease in women? Ann Intern Med 2002, 136:529-533.
20. Rohde LE, Hennekens CH, Ridker PM: Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 1999, 84:1018-1022.
21. Tracy RP, Lemaitre RN, Psaty BM, et al.: Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997, 17:1121-1127.
22. Kuller LH, Tracy RP, Shaten J, Meilahn EN: Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996, 144:537-547.
23. Frohlich M, Imhof A, Berg G, et al.: Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000, 23:1835-1839.
24. Koenig W, Sund M, Frohlich M, et al.: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99:237-242.
25. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
26. Ridker PM, Rifai N, Rose L, et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
27. Pickup JC, Mattok MB, Chusney GD, Burt D: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40:1286-1292.
28. Pradhan AD, Manson JE, Rifai N, et al.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
29. Freeman DJ, Norrie J, Caslake MJ, et al.: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002, 51:1596-1600.
30. Barzilay JI, Spiekerman CF, Koller LH, et al.: Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders: the Cardiovascular Health Study. Diabetes Care 2001, 24:1233-1239.
31. Festa A, D'Agostino RJ, Howard G, et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
32. Visser M, Bouter LM, McQuillan GM, et al.: Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131-2135.
33. Liu S, Manson JE, Buring JE, et al.: Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr 2002, 75:492-498.
34. Tchernof A, Nolan A, Sites CK, et al.: Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002, 105:564-569.
35. Ridker PM, Shih J, Cook TJ, et al.: Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events. Circulation 2002, 105:1776-1779.
36. Dandona P, Aljada A, Mohanty P: The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 2002, 45:924-930.
37. Baldwin AS Jr: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996, 14:649-683.
38. Fath-Ordoubadi F, Beatt KJ: Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997, 96:1152-1156.
39. Malmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997, 314:1512-1515.
40. Haffner SM, Greenberg AS, Weston WM, et al.: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002, 106:679-684.
41. Chu NV, Kong AP, Kim DD, et al.: Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002, 25:542-549.
42. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51:1131-1137.
43. Gurlek A, Bayraktar M, Kirazli S: Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels. Diabetes Care 2000, 23:88-92.
44. Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993, 16:621-629.
45. Aljada A, Garg R, Ghanim H, et al.: Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an anti-inflammatory action? J Clin Endocrinol Metab 2001, 86:3250-3256.
46. Munshi MN, Stone A, Fink L, Fonseca V: Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism 1996, 45:133-135.
47. Fonseca V, Guba SC, Fink LM: Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. Endocr Rev 1999, 20:738-759.
48. Kark JD, Selhub J, Bostom A, et al.: Plasma homocysteine and all-cause mortality in diabetes [letter]. Lancet 1999, 353:1936-1937.
49. Hoogeveen EK, Kostense PJ, Jakobs C, et al.: Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn study. Circ Res 2000, 101:1506-1511.
50. Schnyder G, Roffi M, Flammer Y, et al.: Effect of homocysteine-lowering therapy with folic acid, vitamin B(12), and vitamin B(6) on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 2002, 288:973-979.
51. Dicker-Brown A, Fonseca VA, Fink LM, Kern PA: The effect of glucose and insulin on the activity of methylene tetrahydrofolate reductase and cystathionine-beta-synthase: studies in hepatocytes. Atherosclerosis 2001, 158:297-301.
52. Fonseca V, Keebler M, Dicker-Brown A, et al.: The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine metabolism in Zucker rats. Metabolism 2002, 51:783-786.
53. Meigs JB, Jacques PF, Selhub J, et al.: Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care 2001, 24:1403-1410.
54. Fonseca VA, Mudaliar S, Schmidt B, et al.: Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects. Metabolism 1998, 47:686-689.
55. Franken DG, Boers GH, Blom HJ, et al.: Treatment of mild hyperhomocysteinemia in vascular disease patients. Circ Res 1994, 14:465-470.
56. Malinow MR, Duell PB, Hess DL, et al.: Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998, 338:1009-1015.
57. Desouza C, Keebler M, McNamara DB, Fonseca V: Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs 2002, 62:605-616.